Learn more about the Zepbound® savings card (no Gov`t beneficiaries, terms apply), the Zepbound cash option, and LillyDirect™, an online pharmacy solutions option.

Zepbound ® and its delivery device base and LillyDirect ® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Zepbound is available by prescription only.

Eli Lilly and Company has created a new self-pay pharmacy component of LillyDirect® where patients with a valid, on-label, electronic prescription from the health care provider of their choice can purchase Zepbound 2.5 and 5 mg vials.1

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a reduced- …

Pregnant patients exposed to Zepbound and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).

Zepbound (tirzepatide) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off.

Zepbound is a once-weekly injectable prescription medicine for chronic weight management in adults with an initial body mass index of at least 30 kg/m2 or at least 27 kg/m2 with at least one weight-related comorbid condition.

INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...